Control group:Fruquintinib

Hepatic Arterial Infusion Chemotherapy Combined with Fruquintinib vs. Fruquintinib in the Treatment of Colorectal Cancer with Liver Metastasis Failure of Standard Second-line Chemotherapy: A Phase 2 Randomized Controlled Clinical Study

Fruquintinib combined with bemozumab versus fruquintinib as third-line treatment for advanced metastatic colorectal cancer: A randomized, open-label, single-center Phase II clinical study (RCTS)

A randomized, controlled, multicenter clinical trial of Fruquintinib combined with TAS-102 with Fruquintinib in the treatment of advanced metastatic colorectal cancer with standard treatment failure

An Open-Label, Randomized, Controlled Phase II Clinical Study of Fruquintinib Combined with Cetuximab Beta and Epcoritamab Versus Fruquintinib Monotherapy as Third-Line Treatment for RAS/BRAF Wild-Type Advanced Colorectal Cancer